NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Centessa Pharmaceuticals plc (CNTA) Stock Analysis

Centessa Pharmaceuticals plc (CNTA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CNTA

$40.50

$0.00 (0.00%)

Last trade June 29, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CNTA with… →

CNTA Key Statistics

As of Jun 29, 2026
Trading
Open
$40.50
Previous Close
$40.50
52-Week Range
10.95–40.26
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.14
Valuation
Market Cap
$6.16B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.78
Financials (FY)
Revenue (FY)
$15.00M
Net Income (FY)
−$197.53M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
+208.45%
Dividend and dates
Avg Volume
2.72M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CNTA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+61.94%
2025+49.31%
2024 (partial year)−4.56%

As of June 29, 2026.

CNTA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$15.00M−$197.53M−1316.9%
2024$0.00−$235.76M—
2023$6.85M−$151.09M−2204.7%
2022$0.00−$216.21M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$15.00M—−$207.69M−$197.53M−1316.9%
2024$0.00—−$201.06M−$235.76M—
2023$6.85M—−$171.28M−$151.09M−2204.7%
2022$0.00—−$210.28M−$216.21M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CNTA Valuation vs Biotechnology Median

Median of 656 stocks
MetricCNTABiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Centessa Pharmaceuticals plc (CNTA) carries a market capitalisation of $6.16B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 129.

The 52-week range on file runs from $10.95 to $40.26. The most recent close on file for CNTA is $40.50, dated June 29, 2026. The close was unchanged from the previous session. The latest close sits 269.86% above that 52-week low.

Financial Health

In fiscal 2025, Centessa Pharmaceuticals plc reported revenue of $15.00M. The same year closed with a net loss of $197.53M. The reported profit margin is 0%. Trailing earnings per share are −1.78.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $15.00M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year price return is +208.45%. The stored price history starts on December 19, 2024, and the total return since then is +130.77%. The reported beta is 1.14. Daily returns over the trailing 1 year annualize to a volatility of 67.49%.

Growth & Income

No dividend is on file for CNTA.

So far in 2026 the price is +61.94%. The record holds one complete calendar year, 2025, which returned +49.31%.

Peer Comparison

Centessa Pharmaceuticals plc (CNTA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Centessa Pharmaceuticals plc CNTA $6.16B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Centessa Pharmaceuticals plc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of June 29, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Centessa Pharmaceuticals plc

Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Visit website →